SUNPHARMA's weekly performance was disappointing, with a return of -2.18% and a Sharpe Ratio of -0.21, indicating poor risk-adjusted returns. The stock's volatility was high at 38.91%, and it experienced a max drawdown of -3.6%. Compared to its peers, SUNPHARMA underperformed, with DRREDDY and DIVISLAB posting significantly higher returns. Overall, the stock was riskier than HINDUNILVR but less risky than its other peers.

[Volatility: 38.91%]